Estrategias de intensificación de la farmacoterapia en los trastornos de ansiedad resistentes al tratamiento
Información
- DOI:
- https://doi.org/10.1002/14651858.CD005473.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 18 octubre 2006see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Trastornos mentales comunes
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Jonathan Ipser was responsible for responding to editorial feedback, for writing the methods and results section of the review and for capturing and analysing the data. Nuraan Fakier assisted in double‐checking the trial data captured. Yumna Dhansay completed the background section of the review. Paul Carey and Soraya Seedat provided comprehensive feedback on the review. Dan Stein co‐ordinated and provided feedback on the review. Nuraan Fakier assisted in trial retrieval/selection and in double‐data entry.
Sources of support
Internal sources
-
MRC Unit on Anxiety Disorders, South Africa.
-
University of Cape Town, Cape Town, South Africa.
External sources
-
MRC Research Unit on Anxiety and Stress Disorders, South Africa.
Declarations of interest
The MRC Unit on Anxiety Disorders has been supported by each of the pharmaceutical companies with an interest in psychiatry in South Africa.
Potential conflicts of interest for individual reviewers
Jonathan Ipser has no known conflicts of interest outside of his affiliation by the MRC Unit on Anxiety Disorders.
Paul Carey has received research grants/honoria from Astra Zeneca, Glaxo‐Smithkline, Lundbeck, and Sanofi‐Aventis
Yumna Dhansay has no known conflicts of interest outside of her affiliation with the MRC Unit on Anxiety Disorders.
Soraya Seedat has received support from several companies (including GlaxoSmithKline, Eli‐Lilly, Pfizer, Cephalon, AstraZeneca, Lundbeck) and has participated in several clinical trials.
Nuraan Fakier has no known conflicts of interest outside of her affiliation with the MRC Unit on Anxiety Disorders.
Dan Stein has received research grants and/or consultancy honoraria from Astrazeneca, Eli‐Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, and Wyeth. He has participated in a number of ongoing trials, and has presented data from some of these trials on behalf of the sponsoring companies.
Acknowledgements
The authors are supported by the MRC Research Unit on Anxiety and Stress Disorders (Cape Town, South Africa). We wish to thank Eric Hollander (and Nicolo Rossi), Mendel Fux and colleagues, Stefano Pallanti, and Stefano Erzegovesi for responding to requests for additional data for the review. We would also like to express our gratitude to Luzaan van Wyk and Simon Hagger of AstraZeneca and Mark Pollack for letting us have access to unpublished trials, and the CCDAN editorial base for their assistance. Joy Oliver of the South African Cochrane Centre helped retrieve trial reports for inclusion in the review.
Version history
| Published | Title | Stage | Authors | Version |
| 2006 Oct 18 | Pharmacotherapy augmentation strategies in treatment‐resistant anxiety disorders | Review | Jonathan C Ipser, Paul Carey, Yumna Dhansay, Nuraan Fakier, Soraya Seedat, Dan J Stein | |
| 2005 Jul 20 | Pharmacotherapy augmentation strategies in treatment‐resistant anxiety disorders | Protocol | Yumna Dhansay, Jonathan C Ipser, Dan J Stein | |
